Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

DOI Full Paper Access

100

Citations

26

References

2021

Year

Andrew J.K. Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Gabriela Alperovich, Wenjing Lü, Zailong Wang, Ahmed M. Soliman,

Annals of the Rheumatic Diseases

Abstract

NCT03671148.

References

	Year	Citations

Page 1